Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. März 2026 05:30 ET | Quelle: West Red Lake Gold Mines Ltd.

West Red Lake Gold Appoints Jaclyn Ruptash as Vice President, Communications

West Red Lake Gold Mines announces the appointment of Jaclyn Ruptash as Vice President, Communications, further strengthening its leadership team/
26. März 2026 07:00 ET | Quelle: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Lead clinical candidate IND filing in...
19. März 2026 07:00 ET | Quelle: OKYO Pharma LTD

OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
18. März 2026 10:30 ET | Quelle: Custom Market Insights

[Latest] Global Financial Close Software Market Size/Share Worth USD 18.5 Billion by 2034 at a 8.1% CAGR: Business Research Industry (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Financial Close Software Market grows as enterprises adopt cloud-based automation to streamline financial reporting, compliance, month-end close processes.
17. März 2026 08:00 ET | Quelle: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid...
16. März 2026 06:30 ET | Quelle: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development...